Ratutrelvir: meta-analysis of COVID-19 studies

All studies   Recovery   RCTs   All outcomes  
Meta-analysis1 study · 50 patientsc19early.org

Ratutrelvir for COVID-19

Serious outcome risk
Ratutrelvir
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)14%
RCTs (1)14%
Early (1)14%
00.511.5+
← Ratutrelvir
reduces riskIncreased
risk →
c19early.org
October 2026

Ratutrelvir COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Dokukina (RCT)14%0.86 · 0.76–0.97no recov.32 (n)18 (n)OT1
Early treatment14%0.86 · 0.76–0.9732 (n)18 (n)14% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.014
All studies14%0.86 · 0.76–0.9732 (n)18 (n)14% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.01400.511.52+
1 OT: comparison with other treatment
Rotate screen for more detailsIncrease width for more details
← Ratutrelvir
reduces riskRatutrelvir
increases risk →
c19early.org
October 2026

Ratutrelvir COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Dokukina (RCT)14%0.86 · 0.76–0.97no recov.32 (n)18 (n)OT1
Early treatment14%0.86 · 0.76–0.9732 (n)18 (n)14% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.014
All studies14%0.86 · 0.76–0.9732 (n)18 (n)14% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.01400.511.52+
1 OT: comparison with other treatment
Rotate screen for more detailsIncrease width for more details
← Ratutrelvir
reduces riskRatutrelvir
increases risk →
c19early.org
October 2026

Ratutrelvir COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Dokukina (RCT)14%0.86 · 0.76–0.97no recov.32 (n)18 (n)OT1
Early treatment14%0.86 · 0.76–0.9732 (n)18 (n)14% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.014
All studies14%0.86 · 0.76–0.9732 (n)18 (n)14% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.01400.511.52+
1 OT: comparison with other treatment
Rotate screen for more detailsIncrease width for more details
← Ratutrelvir
reduces riskRatutrelvir
increases risk →